Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal. Nexo Therapeutics (Nexo) announced it has emerged from stealth with $60 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented SpyGlass in the transaction. SpyGlass Pharma announced the closing of $90 million in Series C financing. The financing, which was led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Delve Bio in the transaction. Delve Bio announced it has debuted with $35 million in Series A financing led by Perceptive...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction. Clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised NEA and Abingworth on the transaction. Escient Pharmaceuticals announced that it had raised $120 million through a Series C Financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised lead investor Enavate Sciences and new investor Longitude Capital in the financing. Global pharmaceutical company Zenas BioPharma announced a $118...
You must be a Standard 1 Year member to access this content.
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini represented Aadi Bioscience, Inc. on the deal. Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
You must be a Standard 1 Year member to access this content.
